1	Mark C. Holscher (SBN 139582)	QUINN EMANUEL URQUHART &
	KIRKLAND & ELLIS LLP	SULLIVAN, LLP
2	555 South Flower Street, Suite 3700 Los Angeles, CA 90071	Diane M. Doolittle (Bar No. 142046) dianedoolittle@quinnemanuel.com
3	Telephone (213) 680-8400	Yury Kapgan (Bar No. 218366)
	Facsimile: (213) 680-8500	yurykapgan@quinnemanuel.com
4	Email: mark.holscher@kirkland.com	Kyle Batter (Bar No. 301803)
_		kylebatter@quinnemanuel.com
5	Christopher W. Keegan (SBN 232045)	555 Twin Dolphin Drive, 5th Floor
6	KIRKLAND & ELLIS LLP	Redwood Shores, California 94065
6	555 California Street, Suite 2700 San Francisco, CA 94104	Telephone: (650) 801-5000 Facsimile: (650) 801-5100
7	Telephone: (415) 439-1400	1 desimile. (030) 001 3100
	Facsimile: (415) 439-1500	David M. Elihu (Bar No. 303043)
8	Email: chris.keegan@kirkland.com	davidelihu@quinnemanuel.com
		Jimmy Bieber (Bar No. 301639)
9	Gabor Balassa (admitted pro hac vice)	jimmybieber@quinnemanuel.com
10	Ryan Moorman (admitted <i>pro hac vice</i> ) KIRKLAND & ELLIS LLP	865 South Figueroa Street, 10th Floor Los Angeles, California 90017
10	333 West Wolf Point Plaza	Telephone: (213) 443-3000
11	Chicago, IL 60654	Facsimile: (213) 443-3100
	Telephone: (312) 862-2000	,
12	Facsimile: (312) 862-2200	Counsel for Plaintiff and Counter-Defendant
13	Email: gbalassa@kirkland.com	Nektar Therapeutics
13	Email: ryan.moorman@kirkland.com	
14	Counsel for Defendant and Counter-Claimant	
	Eli Lilly and Company	
15		
16	UNITED STATES DISTRICT COURT	
17	NORTHERN DISTRICT OF CALIFORNIA	
	SAN FRANCISCO DIVISION	
18	22211211	22 0 0 21 122 01 (
19	NEWTAD THED ADELITICS	CASE NO 2.22 CV 02042 ID
	NEKTAR THERAPEUTICS,	CASE NO. 3:23-CV-03943-JD
20	Plaintiff/Counter-Defendant,	STIPULATION AND <del>[PROPOSED]</del> ORDER
21	,	EXTENDING TIME TO FILE OMNIBUS
41	v.	SEALING MOTION RELATED TO
22		DISPOSITIVE MOTIONS AND DAUBERT
	ELI LILLY & CO.,	MOTIONS
23	Defendant/Counter-Claimant.	Judge: Hon. James Donato
24	2 1211 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Treat values 2 chaire
<b>۲</b> ۲		_
25		
26		
27		
- '		
28		

CASE No. 3:23-CV-03943-JD

STIPULATION AND [PROPOSED] ORDER EXTENDING TIME TO FILE OMNIBUS SEALING

MOTION

Pursuant to Civil Local Rule 7-12, Plaintiff Nektar Therapeutics ("Plaintiff") and Defendant Eli Lilly and Company ("Defendant"), by and through their undersigned counsel, hereby stipulate and agree as follows:

WHEREAS, pursuant to Paragraph 31 of this Court's Standing Order for Civil Cases ("Paragraph 31"), on May 19, 2025, the parties submitted a Stipulation and Proposed Order Related to Sealing Procedures ("Original Stipulation") (ECF No. 191) to consolidate all sealing motions related to the briefing into the Omnibus Sealing Motion, for efficiency and to reduce burden on the Court;

WHEREAS, on May 22, 2025, the Court entered an Order approving the Original Stipulation (ECF No. 192), and the parties filed dispositive motions and *Daubert* motions with certain content provisionally under seal consistent with the Court's Order;

WHEREAS, under the Original Stipulation, the parties agreed to jointly file the Omnibus Sealing Motion covering all dispositive motions briefing and *Daubert* briefing by 30 days after the conclusion of briefing, which thereby set a deadline of July 28, 2025 to file the Omnibus Sealing Motion covering all briefing;

WHEREAS, during the course of the dispositive motion and *Daubert* motion briefing, the parties submitted a total of 24 briefs and 254 exhibits and attachments either in redacted form or provisionally under seal in their entirety;

WHEREAS, the parties have been diligently reviewing the 24 briefs and 254 exhibits to ensure the provisionally sealed material conforms with the Court's Standing Order and the applicable legal standards;

WHEREAS, given the volume of briefing and exhibits and the coordination required to reach agreement on a joint submission, including a motion and supporting declarations, the parties respectfully request a short extension of 21 days to finalize their submissions on sealing and to file the joint Omnibus Sealing Motion;

WHEREAS, the 21 day extension to the Omnibus Sealing Motion deadline will have no impact on other case deadlines or the Court's Scheduling Order;

NOW THEREFORE, the parties hereby stipulate and agree, subject to the Court's approval, as follows:

1. The parties shall jointly file one Omnibus Sealing Motion covering all dispositive motions 1 2 briefing and *Daubert* briefing, by no later than August 18, 2025. 3 DATED: July 21, 2025 Respectfully submitted, 4 KIRKLAND & ELLIS LLP 5 6 s/Ryan Moorman Ryan Moorman 7 Counsel for Defendant and Counter-Claimant 8 Eli Lilly and Company 9 DATED: July 21, 2025 Respectfully submitted, 10 QUINN EMANUEL URQUHART & SULLIVAN, LLP 11 12 s/Jimmy Bieber Jimmy Bieber 13 Counsel for Plaintiff and Counter-Defendant 14 Nektar Therapeutics 15 16 ATTESTATION PURSUANT TO CIVIL L.R. 5-1(I)(3) 17 I, Ryan Moorman, am the ECF user whose user ID and password are being used to file this 18 document. I hereby attest that concurrence in the filing of this document has been obtained from each of 19 the other signatories. /s/ Ryan Moorman 20 Ryan Moorman 21 22 23 24 25 26 27 28

PURSUANT TO STIPULATION, IT IS SO ORDEBED.

Dated July 25 , 2025

JAMES BONATO UNITED STATES DISTRICT COURT JUDGE

STIPULATION AND [PROPOSED] ORDER EXTENDING TIME TO FILE OMNIBUS SEALING MOTION